News

October 4, 2017October 4, 2017

First Clinical Trial Testing NBTXR3 Plus Immune Checkpoint Inhibitors to Recruit Patients in the US

News

The late-clinical-stage company Nanobiotix, which works toward developing new cancer treatment approaches, announced that it will soon launch its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors ... Read more

October 3, 2017

Selexis, OSE Team Up to Advance Two Cancer Immunotherapy Programs

News

Selexis and OSE Immunotherapeutics have signed two commercial license agreements (CLAs) to advance the clinical development of two new cancer immunotherapy programs, OSE-172 and OSE-703. The agreement supports the development of ... Read more

October 2, 2017

Researchers Develop Guidelines for Management of CAR T-cell Triggered Toxicities

News

Researchers have developed guidelines for handling the potentially fatal side effects of CAR T-cell therapy, which along with its unprecedented efficacy in treating certain cancers, comes with a high risk ... Read more

September 29, 2017September 29, 2017

IMO-2125, Yervoy Combo Shows Promise in Preclinical Data and Phase 1 Studies

News

Combining IMO-2125 and an anti-CTLA-4 antibody induces long-term systemic anti-cancer immune responses in mice that outperform those seen with either of the treatments alone, according to recent preclinical results presented at ... Read more

September 28, 2017

Adjuvant Opdivo Delays Recurrence in Advanced Melanoma Patients, CheckMate-238 Study Shows

News

Advanced melanoma patients at high risk of recurrence after surgery fare better if given Opdivo (nivolumab) compared to the standard of care Yervoy (ipilimumab), according to data presented at the European Society for ... Read more

September 27, 2017September 27, 2017

Keytruda Approved as First-Line Lung Cancer Treatment in Canada

News

Canadian patients with metastatic non-small cell lung cancer (NSCLC) can now receive Merck‘s Keytruda (pembrolizumab) as their first treatment following a recent approval by health authorities. The approval covers patients who have ... Read more

September 26, 2017September 26, 2017

FDA Grants Accelerated Approval to Keytruda for Gastric Cancer

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Merck’s Keytruda (pembrolizumab) for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The approval ... Read more

September 26, 2017

FDA OKs Opdivo as Liver Cancer Therapy for Patients Who Did Not Respond to Nexavar

News

Patients with the most common liver cancer subtype, hepatocellular carcinoma (HCC), who have not responded to Nexavar (sorafenib), now can be treated with Opdivo (nivolumab), following an accelerated approval granted by the ... Read more

September 25, 2017September 25, 2017

UK’s NICE Approves Opdivo as Second-line NSCLC Treatment through Cancer Drugs Fund

News

Non-small cell lung cancer patients in England and Wales who failed prior chemotherapy can now access Opdivo (nivolumab) as a second-line treatment, following the therapy’s recent approval by the U.K.’s National ... Read more

September 22, 2017September 22, 2017

European Commission Approves Bavencio as First Immunotherapy for Adult Metastatic Merkel Cell Carcinoma

News

The European Commission (EC) has granted Bavencio (avelumab) marketing approval as the first immunotherapy to treat the aggressive skin cancer metastatic Merkel cell carcinoma in adults. The decision will allow an ... Read more